Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Rajman

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Drug Discovery Today|April 15, 2008
PK/PD modelling and simulations: utility in drug developmentIris Rajman
Drug Discovery Today|November 7, 2019
Introducing Project Africa GRADIENTIris Rajman, Oscar Della Pasqua,
Clinical and Translational Science|February 27, 2020
Genetic Diversity in Drug Transporters: Impact in African PopulationsIris Rajman, Laura Knapp, Imad Hanna
Ebiomedicine|February 27, 2017
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug DevelopmentIris Rajman, Laura Knapp, Thomas Morgan, et al.
Drug Discovery Today|January 12, 2020
New paradigm for expediting drug development in AsiaIris Rajman, Masaru Hirano, Wataru Honma, et al.
Plos One|January 29, 2015
Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart diseaseDhayana Dallmeier, Michael J Pencina, Iris Rajman, et al.
BMC Cardiovascular Disorders|August 29, 2013
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical careDietrich Rothenbacher, Michael M Hoffmann, Lutz P Breitling, et al.
European Journal of Clinical Pharmacology|April 17, 2016
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarizationThomas H Langenickel, Pierre Jordaan, Jesika Petruck, et al.
Journal of Clinical Pharmacology|June 16, 2015
Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitorLu Gan, Thomas Langenickel, Jesika Petruck, et al.
Journal of Clinical Pharmacology|November 20, 2014
Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populationsMarion Dahlke, Dik Ng, Masayuki Yamaguchi, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Drug Discovery Today|April 15, 2008
PK/PD modelling and simulations: utility in drug developmentIris Rajman
Drug Discovery Today|November 7, 2019
Introducing Project Africa GRADIENTIris Rajman, Oscar Della Pasqua,
Clinical and Translational Science|February 27, 2020
Genetic Diversity in Drug Transporters: Impact in African PopulationsIris Rajman, Laura Knapp, Imad Hanna
Ebiomedicine|February 27, 2017
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug DevelopmentIris Rajman, Laura Knapp, Thomas Morgan, et al.
Drug Discovery Today|January 12, 2020
New paradigm for expediting drug development in AsiaIris Rajman, Masaru Hirano, Wataru Honma, et al.
Plos One|January 29, 2015
Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart diseaseDhayana Dallmeier, Michael J Pencina, Iris Rajman, et al.
BMC Cardiovascular Disorders|August 29, 2013
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical careDietrich Rothenbacher, Michael M Hoffmann, Lutz P Breitling, et al.
European Journal of Clinical Pharmacology|April 17, 2016
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarizationThomas H Langenickel, Pierre Jordaan, Jesika Petruck, et al.
Journal of Clinical Pharmacology|June 16, 2015
Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitorLu Gan, Thomas Langenickel, Jesika Petruck, et al.
Journal of Clinical Pharmacology|November 20, 2014
Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populationsMarion Dahlke, Dik Ng, Masayuki Yamaguchi, et al.
Pageof 3